| Ytd | -84.87% | |
| 1y | -90.97% |
| Open | 5.21 | Prev Close | 5.43 | Low | 4.46 | High | 5.42 | Mkt Cap | 1.43M |
| Vol | 186.51K | Avg Vol | 2.08M | EPS | -7.96 | P/E | -0.57 | Forward P/E | -0.03 |
| Beta | 2.50 | Short Ratio | 1.07 | Inst. Own | 11.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 7.94 | 200-d Avg | 18.26 | 1yr Est | 3.00 |
Ernexa Therapeutics Inc. (NASDAQ:ERNA) on Wednesday said an independently conducted preclinical stud
Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead o
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while heal
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the tre
Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Signi
US stocks lower, Nasdaq down 1% on Tuesday. Health care shares rise 1.7%. Inflation climbs to 3.8%,